中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
CHINESE JOURNAL OF BIOCHEMICAL PHARMACEUTICS
2015年
4期
132-134
,共3页
人参多糖%GP化疗%非小细胞肺癌
人參多糖%GP化療%非小細胞肺癌
인삼다당%GP화료%비소세포폐암
Ginseng polysaccharide%GP chemotherapy%non-small cell lung cancer
目的：探讨人参多糖注射液辅助GP化疗方案治疗非小细胞肺癌的疗效。方法选择2011年6月～2013年6月收治的非小细胞肺癌患者130例，随机分为2组，每组65例。对照组给予吉西他滨和顺铂（ GP方案）进行治疗，观察组在GP方案的基础上加用人参多糖注射液。连续治疗3个月后，对2组患者的治疗效果、T淋巴细胞亚群、不良反应、生存质量评分进行比较，随访1年后对2组患者的生存率进行比较。结果观察组的总有效率为58.5％，显著优于对照组（41.5％），差异具有统计学意义（χ2＝3.72， P＜0.05）；观察组的CD3、CD4和CD4／CD8均显著高于对照组，差异具有统计学意义（t＝5.735、7.885、7.326，均P＜0.05），而CD8显著低于对照组，差异具有统计学意义（ t＝2.442，P＜0.05）；治疗过程中2组患者的主要不良反应为骨髓抑制（表现为白细胞下降、血小板下降和贫血等症状）和胃肠道反应；治疗后观察组的生存质量评分为（71.5±12.9），显著高于对照组（64.2±12.2），差异具有统计学意义（t＝3.315，P＜0.05）；观察组的1年生存率为63.1％，对照组为52.3％，无显著差异。结论在GP化疗方案的基础上加用人参多糖注射液治疗非小细胞肺癌临床效果显著，免疫力显著增强，副作用风险降低，生存质量好。
目的：探討人參多糖註射液輔助GP化療方案治療非小細胞肺癌的療效。方法選擇2011年6月～2013年6月收治的非小細胞肺癌患者130例，隨機分為2組，每組65例。對照組給予吉西他濱和順鉑（ GP方案）進行治療，觀察組在GP方案的基礎上加用人參多糖註射液。連續治療3箇月後，對2組患者的治療效果、T淋巴細胞亞群、不良反應、生存質量評分進行比較，隨訪1年後對2組患者的生存率進行比較。結果觀察組的總有效率為58.5％，顯著優于對照組（41.5％），差異具有統計學意義（χ2＝3.72， P＜0.05）；觀察組的CD3、CD4和CD4／CD8均顯著高于對照組，差異具有統計學意義（t＝5.735、7.885、7.326，均P＜0.05），而CD8顯著低于對照組，差異具有統計學意義（ t＝2.442，P＜0.05）；治療過程中2組患者的主要不良反應為骨髓抑製（錶現為白細胞下降、血小闆下降和貧血等癥狀）和胃腸道反應；治療後觀察組的生存質量評分為（71.5±12.9），顯著高于對照組（64.2±12.2），差異具有統計學意義（t＝3.315，P＜0.05）；觀察組的1年生存率為63.1％，對照組為52.3％，無顯著差異。結論在GP化療方案的基礎上加用人參多糖註射液治療非小細胞肺癌臨床效果顯著，免疫力顯著增彊，副作用風險降低，生存質量好。
목적：탐토인삼다당주사액보조GP화료방안치료비소세포폐암적료효。방법선택2011년6월～2013년6월수치적비소세포폐암환자130례，수궤분위2조，매조65례。대조조급여길서타빈화순박（ GP방안）진행치료，관찰조재GP방안적기출상가용인삼다당주사액。련속치료3개월후，대2조환자적치료효과、T림파세포아군、불량반응、생존질량평분진행비교，수방1년후대2조환자적생존솔진행비교。결과관찰조적총유효솔위58.5％，현저우우대조조（41.5％），차이구유통계학의의（χ2＝3.72， P＜0.05）；관찰조적CD3、CD4화CD4／CD8균현저고우대조조，차이구유통계학의의（t＝5.735、7.885、7.326，균P＜0.05），이CD8현저저우대조조，차이구유통계학의의（ t＝2.442，P＜0.05）；치료과정중2조환자적주요불량반응위골수억제（표현위백세포하강、혈소판하강화빈혈등증상）화위장도반응；치료후관찰조적생존질량평분위（71.5±12.9），현저고우대조조（64.2±12.2），차이구유통계학의의（t＝3.315，P＜0.05）；관찰조적1년생존솔위63.1％，대조조위52.3％，무현저차이。결론재GP화료방안적기출상가용인삼다당주사액치료비소세포폐암림상효과현저，면역력현저증강，부작용풍험강저，생존질량호。
Objective To discuss the treatment effect of ginseng polysaccharide injection auxiliary GP chemotherapy for patients with non-small cell lung cancer.Methods 130 cases of patients with non-small cell lung cancer from June 2011 to June 2013 were randomly divided into two groups, 65 cases in each group.The control group was given gemcitabine and cisplatin treatment.The observation group were treated with ginseng polysaccharide injection on the basis of the control group.After 3 months of continuous therapy, the therapeutic effect, T-lymphocyte subsets, adverse events, quality of life scores of the two groups were compared, and survival in two groups of patients were also compared after 1 year follow-up.Results The total efficiency and clinical benefit rate in observation group were 58.5%, significantly better than the control group ( 41.5%) , the difference was statistically significant (χ2 =3.72, P<0.05);CD3, CD4 and CD4 /CD8 in observation group were significantly higher than the control group, the differences were statistically significant (t =5.735, 7.885, 7.326, P<0.05), whereas CD8 was significantly lower than the control group, the difference was statistically significant (t=2.442, P<0.05).The main adverse reactions of the two groups of patients during treatment were myelosuppression (WBC and platelet decreasing and anemia ) and gastrointestinal reaction.Score of life quality in observation group was ( 71.5 ±12.9 ) after treatment, significantly higher than the control group (64.2 ±12.2), the difference was statistically significant (t=3.315, P<0.05).1-year survival rate in the observation group were 63.1%, and 52.3% in the control group.Conclusion Ginseng Polysaccharide injection auxiliary GP chemotherapy for non-small cell lung cancer has significantly efficacy, enhances immunity, reduces side effects, better quality of life.
